Details

Autor(en) / Beteiligte

• McHutchison, John G
• Lawitz, Eric J
• Shiffman, Mitchell L
• Muir, Andrew J
• Galler, Greg W
• McCone, Jonathan
• Nyberg, Lisa M
• Lee, William M
• Ghalib, Reem H
• Schiff, Eugene R
• Galati, Joseph S
• Bacon, Bruce R
• Davis, Mitchell N
• Mukhopadhyay, Pabak
• Koury, Kenneth
• Noviello, Stephanie
• Pedicone, Lisa D
• Brass, Clifford A
• Albrecht, Janice K
• Sulkowski, Mark S

Titel

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

Ist Teil von

• The New England journal of medicine, 2009-08, Vol.361 (6), p.580-593

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2009

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In this randomized comparison of treatment with peginterferon alfa-2a, standard-dose peginterferon alfa-2b, and low-dose peginterferon alfa-2b in patients infected with hepatitis C genotype 1, the rates of sustained virologic response and adverse events were similar for all three regimens. In this randomized comparison of treatment with peginterferon alfa-2a, standard-dose peginterferon alfa-2b, and low-dose peginterferon alfa-2b in patients infected with hepatitis C genotype 1, the rates of sustained virologic response and adverse events were similar with all three regimens. Hepatitis C virus (HCV) chronically infects approximately 180 million people worldwide 1 and is a frequent cause of liver disease, including liver failure and hepatocellular carcinoma. 2 HCV treatment is recommended for persons at the greatest risk for progression of liver disease. 3 On the basis of noncomparative studies demonstrating similar safety and efficacy between the two treatments, 4 , 5 consensus guidelines recommend the use of either peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for the treatment of chronic hepatitis C. However, differences between the peginterferons with respect to structural modifications and dosing (weight-adjusted vs. fixed) may lead to important differences in . . .